See more : Acme United Corporation (ACU) Income Statement Analysis – Financial Results
Complete financial analysis of Poxel S.A. (PXXLF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Poxel S.A., a leading company in the Biotechnology industry within the Healthcare sector.
- Petratherm Limited (PTR.AX) Income Statement Analysis – Financial Results
- CTI BioPharma Corp. (CTIC) Income Statement Analysis – Financial Results
- Brødrene A & O Johansen A/S (0RNT.L) Income Statement Analysis – Financial Results
- FS Bancorp, Inc. (FSBW) Income Statement Analysis – Financial Results
- AEON Financial Service Co., Ltd. (AEOJF) Income Statement Analysis – Financial Results
Poxel S.A. (PXXLF)
About Poxel S.A.
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is Imeglimin, an oral drug candidate, which completed Phase III clinical development stage in Japan, as well as in Phase III in the United States and Europe for the treatment of type 2 diabetes that improves pancreatic beta cell function, reduces insulin resistance, and decreases cardiovascular and metabolic disease risk factors, such as heightened blood lipid levels and excess body weight. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH). The company has a licensing agreement with Enyo Pharma S.A.S. for the development of PXL007 (EYP001), a synthetic non-steroidal and non-bile acid FXR agonist that is in Phase II study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.98M | 674.00K | 13.40M | 6.81M | 26.56M | 74.61M | 5.29M | 70.27K | 59.65K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.98M | 672.00K | 59.00K | 551.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.00K | 2.00K | 13.34M | 6.26M | 26.56M | 74.61M | 5.29M | 70.27K | 59.65K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.05% | 0.30% | 99.56% | 91.90% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 20.95M | 13.94M | 27.48M | 29.24M | 44.55M | 58.09M | 24.10M | 20.92M | 9.24M | 7.00M | 9.08M | 8.70M | 10.37M |
| General & Administrative | 5.03M | 4.44M | 10.63M | 9.94M | 7.41M | 4.49M | 3.45M | 3.83M | 2.68M | 941.58K | 616.97K | 555.83K | 788.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.03M | 4.44M | 10.63M | 9.94M | 7.41M | 4.49M | 3.45M | 3.83M | 2.68M | 941.58K | 616.97K | 555.83K | 788.00K |
| Other Expenses | 2.79M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 28.77M | 21.89M | 35.80M | 36.65M | 51.23M | 62.07M | 27.19M | 24.35M | 11.78M | 6.90M | 7.27M | 7.12M | 8.68M |
| Cost & Expenses | 30.75M | 22.56M | 35.86M | 36.65M | 51.23M | 62.07M | 27.19M | 24.35M | 11.78M | 6.90M | 7.27M | 7.12M | 8.68M |
| Interest Income | -437.00K | 17.00K | 48.00K | 382.00K | 222.00K | 368.00K | 63.50K | 261.68K | 241.92K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 5.71M | 3.81M | 2.95M | 1.67M | 185.00K | 28.00K | 46.51K | 479.57K | 856.56K | 371.38K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 17.20M | 555.00K | 556.00K | 551.00K | 424.00K | 62.00K | 37.90K | 32.01K | 22.98K | 12.34K | 15.39K | 15.34K | 13.68K |
| EBITDA | -12.17M | -27.04M | -22.36M | -29.72M | -25.28M | 1.47M | -21.87M | -23.15M | -11.31M | -13.63M | -7.26M | -7.10M | -8.67M |
| EBITDA Ratio | -614.49% | -3,203.26% | -157.30% | -453.78% | -90.97% | 16.89% | -419.91% | -34,115.64% | -19,255.19% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -28.76M | -21.89M | -22.46M | -29.85M | -24.67M | 12.54M | -21.90M | -24.28M | -11.72M | -6.90M | -7.27M | -7.12M | -8.68M |
| Operating Income Ratio | -1,451.99% | -3,247.77% | -167.67% | -438.54% | -92.90% | 16.81% | -414.02% | -34,558.20% | -19,649.54% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -6.32M | -9.51M | -1.30M | -1.98M | -1.07M | 13.29M | -396.11K | -200.61K | -905.06K | -7.19M | -13.18M | -18.71K | 57.60K |
| Income Before Tax | -35.09M | -31.40M | -23.76M | -31.82M | -25.74M | 13.60M | -22.30M | -24.48M | -12.24M | -14.08M | -20.45M | -7.14M | -8.62M |
| Income Before Tax Ratio | -1,771.23% | -4,658.16% | -177.35% | -467.56% | -96.93% | 18.23% | -421.50% | -34,843.71% | -20,521.40% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 2.00K | 2.00K | 2.00K | 36.00K | 1.00K | 77.00K | -349.42K | 278.96K | 212.26K | -6.74M | 4.00 | 1.00 | 0.00 |
| Net Income | -35.09M | -31.40M | -23.76M | -31.86M | -25.74M | 13.53M | -22.30M | -24.48M | -12.24M | -14.08M | -20.45M | -7.14M | -8.62M |
| Net Income Ratio | -1,771.33% | -4,658.46% | -177.38% | -468.09% | -96.93% | 18.13% | -421.50% | -34,843.71% | -20,521.40% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.00 | -1.08 | -0.83 | -1.16 | -0.99 | 0.54 | -0.97 | -1.16 | -0.68 | -0.80 | -1.16 | -0.72 | -0.86 |
| EPS Diluted | 0.00 | -1.08 | -0.83 | -1.16 | -0.99 | 0.54 | -0.97 | -1.16 | -0.68 | -0.80 | -1.16 | -0.72 | -0.86 |
| Weighted Avg Shares Out | 31.74M | 29.08M | 28.64M | 27.53M | 25.94M | 24.83M | 23.03M | 21.07M | 17.92M | 17.63M | 17.63M | 9.98M | 9.98M |
| Weighted Avg Shares Out (Dil) | 31.74M | 29.08M | 28.64M | 27.53M | 25.94M | 24.83M | 23.03M | 21.07M | 17.92M | 17.63M | 17.63M | 9.98M | 9.98M |
Poxel Reports Financial Results for Full Year 2023 and Provides Corporate Update
Poxel Announces Agreement with OrbiMed to Monetize a portion of TWYMEEG® Royalties for USD 50 million
Poxel Reports Revenue for the Second Quarter and First Half 2024 and Provides Corporate Update
Sumitomo Pharma and Poxel Announce Topline Results from Post-Marketing Clinical Study on TWYMEEG® for the Treatment of Type 2 Diabetes in Japan
Poxel Provides an Update on Its Financial Position for the Second Quarter and First Half of 2024 and Announces the Rescheduling of Its Annual General Meeting
Poxel Reports Revenue for the First Quarter 2024 and Provides Corporate Update
Poxel Provides a Financial Update for the First Quarter 2024 and Announces the Postponement of its 2023 Full-Year Results Release
Source: https://incomestatements.info
Category: Stock Reports